The study focuses on adults who have stable Coronary Artery disease and an increased level of a blood protein called hsCRP, which signals inflammation. Some participants may also have other conditions such as Chronic Kidney Disease or Heart Failure. The experimental medicine being tested is identified by the code name YMI024. A control group will receive an inactive substance known as placebo. The goal is to see whether YMI024 can lower inflammation without causing safety problems.
The purpose of the trial is to evaluate how different doses of YMI024 affect the reduction of inflammatory markers, especially the proteins IL-6 and hsCRP, compared with placebo. IL-6 is a protein that the body releases during inflammation, and hsCRP is a blood test that measures overall inflammation level. By measuring changes in these proteins, researchers can tell if the medicine is working.
Participants will be assigned by chance to receive either the study drug at one of several dose levels or the placebo, and neither the participants nor the study staff will know which one is given (double‑blind). Over several weeks, they will attend clinic visits where blood samples are taken to check IL-6, hsCRP, and other safety labs, and an ECG will be performed to monitor heart rhythm. Information on any side effects and vital signs will be recorded throughout the treatment period.
Germany 
